Wnt10b activates the wnt, notch, and NFIκB pathways in u2os osteosarcoma cells

Journal of Cellular Biochemistry

Volumn 112, Issue 5, 2011, Pages 1392-1402

  Mödder, Ulrike I ^a   Oursler, Merry Jo ^a   Khosla, Sundeep ^a   Monroe, David G ^a  

^a MAYO CLINIC   (United States)

Author keywords

bone; microarray; notch; osteosarcoma; Wnt10b

Indexed keywords

ENDOTHELIN 1; EOTAXIN 2; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; JAGGED1; NOTCH RECEPTOR; NOTCH1 RECEPTOR; SCLEROSTIN; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; WNT10B PROTEIN; WNT3A PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 79953711145     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23048     Document Type: Article

References (47)

1. Baksh D, Boland GM, Tuan RS,. 2007. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem 101: 1109-1124. (Pubitemid 47253714)
2. Baron R, Rawadi G,. 2007. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148: 2635-2643. (Pubitemid 46984775)
3. Bash J, Zong W-X, Banga S, Rivera A, Ballard DW, Ron Y, Gelinas C,. 1999. Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J 18: 2803-2811. (Pubitemid 29233952)
4. Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA,. 2005. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA 102: 3324-3329. (Pubitemid 40328044)
5. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA,. 2007. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22: 1924-1932. (Pubitemid 351229309)
6. Boland GM, Perkins G, Hall DJ, Tuan RS,. 2004. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93: 1210-1230. (Pubitemid 44264134)
7. Boyce BF, Li P, Yao Z, Zhang Q, Badell IR, Schwarz EM, O'Keefe RJ, Xing L,. 2005. TNF-alpha and pathologic bone resorption. Keio J Med 54: 127-131.
8. Bruheim S, Xi Y, Ju J, Fodstad O,. 2009. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res 15: 7161-7169.
9. Chen J, Moloney DJ, Stanley P,. 2001. Pringe modulation of Jagged1-induced Notch signaling requires the action of beta 4galactosyltransferase-1. Proc Natl Acad Sci USA 98: 13716-13721. (Pubitemid 33115964)
10. Chen K, Fallen S, Abaan HO, Hayran M, Gonzalez C, Wodajo F, MacDonald T, Toretsky JA, Uren A,. 2008. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer 51: 349-355.
11. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G,. 2005. Breast cancer metastasis supressor 1 inhibits gene expression by targeting nuclear factor-kapppB activity. Cancer Res 65: 3586-3595. (Pubitemid 40616334)
12. Glasser DB, Lane JM, Huvos AG, Marcove RC, Rosen G,. 1992. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer 69: 698-708.
13. Goorin AM, Delorey MJ, Lack EE, Gelber RD, Price K, Cassady JR, Levey R, Tapper D, Jaffe N, Link M, Abelson HT,. 1984. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: Analysis of 32 patients. J Clin Oncol 2: 425-431. (Pubitemid 14075972)
14. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, Peabody T, Simon MA, Montag AG, He T-C,. 2002. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102: 338-342. (Pubitemid 35265873)
15. Hicks C, Johnston SH, diSibio G, Collazo A, Vogt TF, Weinmaster G,. 2000. Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2. Nat Cell Biol 2: 515-520.
16. Hilton MJ, Tu X, Wu X, Bai S, Zhao H, Kobayashi T, Kronenberg HM, Teitelbaum SL, Ross FP, Kopan R, Long F,. 2008. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med 14: 306-314. (Pubitemid 351347911)
17. Iqbal J, Sun L, Kumar TR, Blair HC, Zaidi M,. 2006. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci USA 103: 14925-14930. (Pubitemid 44527830)
18. Itasaki N, Hoppler S,. 2010. Crosstalk between Wnt and bone morphogenic protein signaling: A turbulant relationship. Dev Dyn 239: 16-33.
19. Iwao K, Miyoshi Y, Nawa G, Yoshikawa H, Ochi T, Nakamura Y,. 1999. Frequent beta-catenin abnormalitites in bone and soft-tissue tumors. Jpn J Cancer Res 90: 205-209. (Pubitemid 29112321)
20. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K,. 2003. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20: 525-529. (Pubitemid 37297180)
21. Johnson ML, Kamel MA,. 2007. The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19: 376-382. (Pubitemid 46884195)
22. Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, Boyce BF, Xing L,. 2006. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 281: 4326-4333. (Pubitemid 43847863)
23. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PFM, Simmons PJ, Dawid IB, Thomas DM,. 2009. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119: 837-851.
24. Kim TH, Xiong H, Zhang Z, Ren B,. 2005. beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 24: 597-604. (Pubitemid 40188564)
25. Lane TF, Leder P,. 1997. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15: 2133-2144. (Pubitemid 27493902)
26. Leung JY, Kolligs FT, Ru R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER,. 2002. Activation of AXIN2 expression by beta-catenin-T cell factor. J Biol Chem 277: 21657-21665.
27. Link MP, Gebhardt MC, Meyers PA,. 2002. Osteosarcoma. In:, Pizzo PA, Poplack DG, editorss. Principles and practice of pediatric oncology. Baltimore: Lippincott Williams and Wilkins. pp 1051-1089.
28. Maier MM, Gessler M,. 2000. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new notch target genes. Biochem Biophys Res Commun 275: 652-660.
29. Man T-K, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong K-K, Lau CC,. 2005. Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65: 8142-8150. (Pubitemid 41330577)
30. Mandal D, Srivastava A, Mahlum E, Desai D, Maran A, Yaszemski MJ, Jalal SM, Gitelis S, Bertoni F, Damron T, Irwin R, O'Connor M, Schwartz H, Bolander ME, Sarkar G,. 2007. Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. Gene 386: 131-138. (Pubitemid 44932210)
31. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos A, Meyers PA, LaFleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, MacDonald TJ, Gorlick R, Stephan DA,. 2005. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754. (Pubitemid 40478600)
32. Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, Wang Y, Stanley P, Irvine KD, Haltiwanger RS, Vogt TF,. 2000. Fringe is a glycosyltransferase that modifies Notch. Nature 406: 369-375. (Pubitemid 30625549)
33. Monroe DG, Getz BJ, Johnsen SA, Riggs BL, Khosla S, Spelsberg TC,. 2003. Estrogen receptor isoform-specific regulation of endogenous gene expression in human osteoblastic cell lines expressing either ERalpha or ERbeta. J Cell Biochem 90: 315-326. (Pubitemid 37222200)
34. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y,. 2004. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 24: 647-655.
35. O'Donoghue LE, Pittsyn AA, Kamstock DA, Siebert J, Thomas RS, Duval DL,. 2010. Expression profiling in canine osteosarcoma: Identification of biomarkers and pathways associated with outcome. BMC Cancer 10: 506.
36. Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G,. 2010. Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69: 284-290.
37. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N,. 2008. Blocking TNF-alpha in mice reduces colorectal carcinogenensis associated with chronic colitis. J Clin Invest 118: 560-570. (Pubitemid 351206546)
38. Reya T, Clevers H,. 2005. Wnt signalling in stem cells and cancer. Nature 434: 843-850. (Pubitemid 40558990)
39. Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernandez-Majada V, Grilli A, Lopex-Bigas N, Bellora N, Alba MM, Torres F, Dunach M, Sanjuan X, Gonzales S, Gridley T, Capella G, Bigas A, Espinosa L,. 2009. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 106: 6315-6320.
40. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH,. 2010. Wnt inhibitory factor1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther 9: 731-741.
41. Selvarajah G, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol JA,. 2009. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer 8: 72-90.
42. Stevens JR, Miranda-Carboni GA, Singer MA, Brugger SM, Lyons KM, Lane TF,. 2010. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J Bone Miner Res 25: 2138-2147.
43. Tezuka KI, Yasuda M, Watanabe N, Morimura N, Kuroda K, Miyatani S, Hozumi N,. 2002. Stimulation of osteoblastic cell differentiation by Notch. J Bone Miner Res 17: 231-239. (Pubitemid 34087655)
44. Walters DK, Steinmann P, Langsam B, Schmutz S, Born W, Fuchs B,. 2008. Identification of potential chemoresistance genes in osteosarcoma. Anticancer Res 28: 673-679. (Pubitemid 351578907)
45. Westendorf JJ, Kahler RA, Schroeder TM,. 2004. Wnt signaling in osteoblasts and bone diseases. Gene 341: 19-39. (Pubitemid 39335880)
46. Wielenga VJM, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST,. 1999. Expression of CD44 in APc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515-523. (Pubitemid 29094101)
47. Zanotti S, Canalis E,. 2010. Notch and skeleton. Mol Cell Biol 30: 886-896.